“…were synthesized to target the Kv1.3 channel as a new therapy for MS. However, novel peptides remain required for sufficient specificity to distinguish between Kv1.3 and other related Kv1.x channels (16,17). Moreover, although Kv1.3 blocker peptides, such as ShK (a 35-AA polypeptide isolated from the sea anemone Stichodactyla helianthus), efficiently attenuate the severity of experimental autoimmune encephalomyelitis (EAE), a model for MS (18,19), the mechanisms underlying the peptidemediated inhibition of activation and proliferation of primary T EM cells derived from the EAE model are poorly understood.…”